Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …

The results from the RATIFY trial (ClinicalTrials. gov: NCT00651261; CALGB 10603)
showed that midostaurin combined with standard chemotherapy significantly improved …

FLT3 mutations are the most common genetic aberrations found in acute myeloid leukemia
(AML) and associated with poor prognosis. Since the discovery of FLT3 mutations and their …

FLT 3 mutations are present in about one‐third of patients with acute myeloid leukemia
(AML). Several FLT 3 inhibitors have been used in clinical trials, and these include …

Internal tandem duplications and tyrosine kinase mutations in the fms-like tyrosine kinase 3
(FLT3) receptor can occur in acute myeloid leukemia (AML) and portend a poor prognosis …

Midostaurin and gilteritinib are FLT3 inhibitors that have been recently approved for use in
FLT3-mutant acute myeloid leukemia (AML). These approved drugs represent a new …

The prospective randomized, placebo-controlled CALGB 10603/RATIFY trial (Alliance)
demonstrated a statistically significant overall survival benefit from the addition of …

In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients
less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved …

Background: Midostaurin (M) is a multi-targeted small molecule FLT3 inhibitor which has
single agent activity in both internal tandem duplication (ITD) and tyrosine kinase domain …

Activating mutations in FMS-like tyrosine kinase 3 (FLT3), including internal tandem
duplications (ITDs) and tyrosine kinase domain (TKD) mutations, are common in patients …